Lilly rides Mounjaro, Zepbound to better
Time:2024-05-22 00:20:55 Source:sportViews(143)
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Previous:Benedict Cumberbatch looks suave as he joins his co
Next:Forensic psychiatrist reveals the different types of stalkers
You may also like
- Tom Brady and Jay
- Deep sea expedition uncovers more than 50 never
- Liaoning withstand Shanxi rally to win in OT
- China's railways handle 16.47M passenger trips on Monday
- Bella Hadid goes braless in a thigh
- Zhang makes history to reach 2nd round at Monte Carlo
- China storms to quarters, thrilling matchups await
- Game on for tourism bureaus across China after Harbin travel frenzy
- The unstoppable duo of Emma Stone and Yorgos Lanthimos